ImmunoGen, Inc. (IMGN) News
Filter IMGN News Items
IMGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IMGN News Highlights
- For IMGN, its 30 day story count is now at 9.
- Over the past 27 days, the trend for IMGN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about IMGN are ADC and MD.
Latest IMGN News From Around the Web
Below are the latest news stories about ImmunoGen Inc that investors may wish to consider to help them evaluate IMGN as an investment opportunity.
Antibody Drug Conjugates Market Expoler Future Growth With Top Key Players like Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc.Antibody drug conjugate (ADC) is a class of biopharmaceutical drugs indicated as a targeted therapy for treating cancer. ADC is are designed to kill only cancer cells and spare healthy cells, which makes it more effective than traditional cancer treatment |
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating ResultsWALTHAM, Mass., October 14, 2021--ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results |
ImmunoGen: Important Catalysts AheadI covered ImmunoGen (IMGN) twice in the last couple years. In 2019, I discussed the company’s leadership position in ADC technology and its list of licensing partners. I discussed why it failed the FORWARD 1 trial, and the then soon-to-begin SOROYA trial in patients with high FRα expression. In my... |
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., October 01, 2021--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ImmunoGen Appoints Helen M. Thackray, MD to its Board of DirectorsWALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors |
Leerink Partners Stick to Their Hold Rating for Immunogen By Investing.comLeerink Partners Stick to Their Hold Rating for Immunogen |
ImmunoGen (IMGN) Q2 Loss Narrower Than Expected, Revenues LagImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. |
ImmunoGen, inc (IMGN) Q2 2021 Earnings Call TranscriptAt this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, our CFO. |
ImmunoGen (IMGN) Reports Q2 Loss, Misses Revenue EstimatesImmunoGen (IMGN) delivered earnings and revenue surprises of 16.67% and -10.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? |
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial ResultsWALTHAM, Mass., July 30, 2021--ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results |